Healthcare companies by risk reading
Healthcare companies by risk reading: 1,214 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 1 September 2026.
Composite readings for 8,308 companies, recomputed 1 September 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| AROVELLA THERAPEUTICS E4NA | 65 | Stretched | Healthcare | Australia | 3 / 6 | $50M |
| MeVis Medical Solutions AG M3V | 39 | Normal | Healthcare | Germany | 4 / 6 | $50M |
| Precipio Inc PRPO | 32 | Normal | Healthcare | United States | 4 / 6 | $50M |
| Tscan Therapeutics Inc TCRX | 64 | Stretched | Healthcare | United States | 5 / 6 | $49M |
| SVAS BIOSANA SVS.MI | 32 | Normal | Healthcare | Italy | 5 / 6 | $49M |
| S H L Telemedicine Ltd SHLTN | 51 | Elevated | Healthcare | Israel | 5 / 6 | $49M |
| B.M.P. PHARMA TRAD (BMP.SG) BMP | 37 | Normal | Healthcare | Germany | 4 / 6 | $49M |
| Seres Therapeutics Inc MCRB | 69 | Stretched | Healthcare | United States | 4 / 6 | $48M |
| MACH7 Technologies Ltd M7T | 83 | Acute | Healthcare | United States | 4 / 6 | $48M |
| Nasus Pharma Ltd NSRX | 40 | Elevated | Healthcare | Israel | 4 / 6 | $48M |
| Precision Optics Corp Inc POCI | 63 | Stretched | Healthcare | United States | 5 / 6 | $47M |
| Solasia Pharma K.K 9SO | 51 | Elevated | Healthcare | Japan | 4 / 6 | $47M |
| Karyopharm Therapeutics Inc KPTI | 38 | Normal | Healthcare | United States | 5 / 6 | $47M |
| Aiforia Technologies Oyj AIFORIA | 61 | Stretched | Healthcare | Finland | 5 / 6 | $47M |
| Hikma Pharmaceuticals PLC HIK | 36 | Normal | Healthcare | United Kingdom | 5 / 6 | $47M |
| Biohit Oyj B BIOBV | 28 | Normal | Healthcare | Finland | 5 / 6 | $47M |
| Nephros Inc NEPH | 20 | Normal | Healthcare | United States | 5 / 6 | $46M |
| biote Corp - Class A BTMD | 29 | Normal | Healthcare | United States | 5 / 6 | $45M |
| Metagenomi Inc MGX | 60 | Stretched | Healthcare | United States | 5 / 6 | $45M |
| ONCOTHERAPY SCIENCE INC. 30O | 66 | Stretched | Healthcare | Japan | 4 / 6 | $44M |
| FARMAE S.P.A. U5Y | 35 | Normal | Healthcare | Italy | 5 / 6 | $44M |
| NicOx S.A. ALCOX | 14 | Contained | Healthcare | France | 4 / 6 | $43M |
| Mereo Biopharma Group Plc MREO | 69 | Stretched | Healthcare | United Kingdom | 4 / 6 | $43M |
| Milestone Scientific Inc MLSS | 39 | Normal | Healthcare | United States | 5 / 6 | $43M |
| InspireMD Inc NSPR | 58 | Elevated | Healthcare | United States | 5 / 6 | $42M |
| Novacyt ALNOV | 44 | Elevated | Healthcare | France | 5 / 6 | $42M |
| Ekso Bionics Holdings Inc EKSO | 74 | Stretched | Healthcare | United States | 5 / 6 | $42M |
| Botanix Pharmaceuticals Ltd BOT | 63 | Stretched | Healthcare | Australia | 4 / 6 | $41M |
| Petmed Express Inc PETS | 50 | Elevated | Healthcare | United States | 4 / 6 | $41M |
| Oncoinvent ASA ONCIN | 41 | Elevated | Healthcare | Norway | 5 / 6 | $41M |
| QT Imaging Holdings Inc Com QTI | 37 | Normal | Healthcare | United States | 5 / 6 | $40M |
| Little Green Pharma Ltd LGP | 22 | Normal | Healthcare | Australia | 4 / 6 | $40M |
| Incannex Healthcare Inc IXHL | 57 | Elevated | Healthcare | Australia | 4 / 6 | $40M |
| Scilex Holding Company SCLX | 75 | Stretched | Healthcare | United States | 4 / 6 | $39M |
| CLOUDR GROUP LTD. H3L | 66 | Stretched | Healthcare | China | 5 / 6 | $39M |
| Navamedic ASA NAVA | 31 | Normal | Healthcare | Norway | 5 / 6 | $38M |
| Elutia Inc - Class A ELUT | 80 | Acute | Healthcare | United States | 4 / 6 | $38M |
| DocGo Inc DCGO | 43 | Elevated | Healthcare | United States | 4 / 6 | $38M |
| MDxHealth SA MDXH | 39 | Normal | Healthcare | Belgium | 5 / 6 | $37M |
| Harvard Bioscience Inc HBIO | 53 | Elevated | Healthcare | United States | 4 / 6 | $37M |
| Aligos Therapeutics Inc ALGS | 64 | Stretched | Healthcare | United States | 5 / 6 | $37M |
| Abingdon Health Plc ABDX | 31 | Normal | Healthcare | United Kingdom | 5 / 6 | $36M |
| Q linea AB QLINEA | 98 | Acute | Healthcare | Sweden | 3 / 6 | $36M |
| China Pharma Holdings Inc CPHI | 63 | Stretched | Healthcare | China | 5 / 6 | $36M |
| Q-linea AB (publ) 3F80 | 98 | Acute | Healthcare | Sweden | 3 / 6 | $36M |
| Generation Bio Company GBIO | 56 | Elevated | Healthcare | United States | 5 / 6 | $36M |
| CervoMed Inc CRVO | 69 | Stretched | Healthcare | United States | 3 / 6 | $36M |
| Mauna Kea Technologies SAS ALMKT | 47 | Elevated | Healthcare | France | 5 / 6 | $35M |
| Genoway ALGEN | 38 | Normal | Healthcare | France | 5 / 6 | $35M |
| OneMedNet Corp ONMD | 66 | Stretched | Healthcare | United States | 5 / 6 | $34M |
| Cryo-Cell International Inc CCEL | 47 | Elevated | Healthcare | United States | 4 / 6 | $34M |
| Baird Medical Investment Holdings Ltd . BDMD | 80 | Acute | Healthcare | China | 5 / 6 | $34M |
| Gensight Biologics SA SIGHT | 84 | Acute | Healthcare | France | 5 / 6 | $34M |
| SkinBioTherapeutics PLC SBTX | 32 | Normal | Healthcare | United Kingdom | 5 / 6 | $33M |
| Bioretec Oy BRETEC | 75 | Stretched | Healthcare | Finland | 5 / 6 | $33M |
| ContextVision AB CONTX | 22 | Normal | Healthcare | Sweden | 4 / 6 | $33M |
| TELA Bio Inc TELA | 39 | Normal | Healthcare | United States | 5 / 6 | $33M |
| Nortech Systems Inc NSYS | 49 | Elevated | Healthcare | United States | 5 / 6 | $33M |
| Rockwell Medical Inc RMTI | 46 | Elevated | Healthcare | United States | 5 / 6 | $33M |
| PAVmed Inc PAVM | 83 | Acute | Healthcare | United States | 5 / 6 | $33M |
| Actinium Pharmaceuticals Inc ATNM | 68 | Stretched | Healthcare | United States | 4 / 6 | $32M |
| Kyntra Bio Inc KYNB | 82 | Acute | Healthcare | United States | 3 / 6 | $32M |
| Heramed Ltd HMD | 57 | Elevated | Healthcare | Australia | 4 / 6 | $31M |
| Diagnostic Medical Systems SA ALDMS | 30 | Normal | Healthcare | France | 5 / 6 | $31M |
| Avecho Biotechnology Limited OEZ | 70 | Stretched | Healthcare | Australia | 4 / 6 | $31M |
| Accuray Inc ARAY | 55 | Elevated | Healthcare | United States | 5 / 6 | $31M |
| BioAffinity Technologies Inc BIAF | 61 | Stretched | Healthcare | United States | 5 / 6 | $31M |
| Implanet SA ALIMP | 44 | Elevated | Healthcare | France | 5 / 6 | $31M |
| IGC Pharma Inc IGC | 39 | Normal | Healthcare | United States | 5 / 6 | $31M |
| Sangamo Therapeutics Inc SGMO | 85 | Acute | Healthcare | United States | 5 / 6 | $31M |
| genedrive plc GDR | 36 | Normal | Healthcare | United Kingdom | 5 / 6 | $30M |
| Advicenne ALDVI | 35 | Normal | Healthcare | France | 5 / 6 | $30M |
| P3 Health Partners Inc - Class A PIII | 39 | Normal | Healthcare | United States | 3 / 6 | $30M |
| D. Western Therapeutics Institute Inc 6DW | 43 | Elevated | Healthcare | Japan | 5 / 6 | $28M |
| Ikonisys SA ALIKO | 65 | Stretched | Healthcare | France | 5 / 6 | $28M |
| IRLAB Therapeutics AB (publ) IRLAB-A | 52 | Elevated | Healthcare | Sweden | 4 / 6 | $28M |
| SKINBIO THERAP LS-01 5KW | 33 | Normal | Healthcare | United Kingdom | 5 / 6 | $28M |
| Plus Therapeutics Inc PSTV | 69 | Stretched | Healthcare | United States | 5 / 6 | $26M |
| Entero Therapeutics Inc GRDX | 77 | Stretched | Healthcare | United Kingdom | 3 / 6 | $26M |
| ENvue Medical Inc FEED | 64 | Stretched | Healthcare | United States | 4 / 6 | $26M |
| Oncosil Medical Ltd OSL | 37 | Normal | Healthcare | Australia | 4 / 6 | $25M |
| TherapeuticsMD Inc TXMD | 38 | Normal | Healthcare | United States | 3 / 6 | $25M |
| Evaxion Biotech A/S EVAX | 24 | Normal | Healthcare | Denmark | 5 / 6 | $25M |
| Ropharma Bras RPH | 26 | Normal | Healthcare | Romania | 5 / 6 | $25M |
| Aytu BioPharma Inc AYTU | 57 | Elevated | Healthcare | United States | 4 / 6 | $25M |
| ARECOR THERAPEUTICS -01 6UI | 60 | Stretched | Healthcare | United Kingdom | 5 / 6 | $24M |
| RENALYTIX PLC LS-0025 2O9 | 75 | Stretched | Healthcare | United Kingdom | 4 / 6 | $24M |
| Microba Life Sciences Limited F3Y | 26 | Normal | Healthcare | Australia | 4 / 6 | $24M |
| PMGC Holdings Inc ELAB | 84 | Acute | Healthcare | United States | 4 / 6 | $24M |
| Vitasora Health Ltd VHL | 56 | Elevated | Healthcare | Australia | 4 / 6 | $23M |
| Cambridge Cognition Holdings Plc COG | 51 | Elevated | Healthcare | United Kingdom | 5 / 6 | $23M |
| ARTERRA BIOSCIENCE ARBS.MI | 18 | Contained | Healthcare | Italy | 5 / 6 | $23M |
| Intrasense ALINS | 66 | Stretched | Healthcare | France | 4 / 6 | $23M |
| ALTAO ALTAO | 42 | Elevated | Healthcare | France | 5 / 6 | $23M |
| Rua Life Sciences PLC RUA | 32 | Normal | Healthcare | United Kingdom | 5 / 6 | $23M |
| Maternus-Kliniken Aktiengesellschaft MAK | 44 | Elevated | Healthcare | Germany | 5 / 6 | $23M |
| Inspiration Healthcare Group PLC IHC | 41 | Elevated | Healthcare | United Kingdom | 5 / 6 | $22M |
| Allarity Therapeutics Inc ALLR | 69 | Stretched | Healthcare | United States | 4 / 6 | $22M |
| HELYX INDUSTRIES HLX.MI | 40 | Elevated | Healthcare | Italy | 5 / 6 | $22M |
| IXICO PLC IXI | 59 | Elevated | Healthcare | United Kingdom | 5 / 6 | $22M |
By sector
Industrials 1,536Technology 1,292Healthcare 1,214Consumer Cyclical 1,116Basic Materials 577Communication Services 565Real Estate 552Consumer Defensive 536Energy 356Utilities 232
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.